Compass Therapeutics (CMPX) Stock Forecast & Price Target

Compass Therapeutics Inc. has demonstrated promising outcomes in its clinical trials, with notable higher response rates observed in refractory colorectal cancer populations compared to standard anti-VEGF therapies, indicating potential for expansion into additional solid tumor indications. The company's ongoing research and development efforts, although resulting in a 49% increase in expenses to $12.8 million, are mitigated by a decrease in general and administrative expenses, allowing for a focused investment in product development. Furthermore, the differentiated safety profile of CTX-8371, alongside the prospect of accelerated regulatory pathways for various indications, positions Compass Therapeutics favorably for potential growth and substantial upside in its stock performance.

Compass Therapeutics Inc. has reported a significant increase in net loss, rising to $14.3 million in Q3 2025 from $10.5 million in the same quarter of the previous year, primarily driven by elevated R&D expenses linked to CTX-10726 manufacturing and IND-enabling studies. The company's pipeline faces challenges as product candidates, including the VEGF/DLL4 bispecific dilpacimab, have demonstrated poor tolerability and efficacy, evidenced by adverse events such as gastrointestinal perforation. Additionally, the uncertainty surrounding overall survival metrics, with only a 40-50% probability of statistical significance, raises concerns about the effectiveness of their treatments, further contributing to a negative outlook on the company's financial performance and stock prospects.